Business Description
Cardiff Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US8972384080
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 34.82 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.48 | |||||
Beneish M-Score | -3.62 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.1 | |||||
3-Year EBITDA Growth Rate | -3.8 | |||||
3-Year EPS without NRI Growth Rate | 4.5 | |||||
3-Year FCF Growth Rate | 3.9 | |||||
3-Year Book Growth Rate | -23.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 18.3 | |||||
9-Day RSI | 30.67 | |||||
14-Day RSI | 39.67 | |||||
6-1 Month Momentum % | 485.13 | |||||
12-1 Month Momentum % | 306.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.41 | |||||
Quick Ratio | 7.41 | |||||
Cash Ratio | 7.17 | |||||
Days Sales Outstanding | 313.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.7 | |||||
Shareholder Yield % | 0.31 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -9305.74 | |||||
Net Margin % | -8492.01 | |||||
FCF Margin % | -6449.01 | |||||
ROE % | -47.42 | |||||
ROA % | -42.26 | |||||
ROIC % | -616.78 | |||||
ROC (Joel Greenblatt) % | -1384.93 | |||||
ROCE % | -50.94 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 399 | |||||
PB Ratio | 2.56 | |||||
Price-to-Tangible-Book | 2.45 | |||||
EV-to-EBIT | -2.4 | |||||
EV-to-EBITDA | -2.42 | |||||
EV-to-Revenue | 223.1 | |||||
EV-to-Forward-Revenue | 141.77 | |||||
EV-to-FCF | -3.36 | |||||
Price-to-Median-PS-Value | 1.97 | |||||
Price-to-Net-Current-Asset-Value | 2.59 | |||||
Price-to-Net-Cash | 2.7 | |||||
Earnings Yield (Greenblatt) % | -41.63 | |||||
FCF Yield % | -17.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cardiff Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.453 | ||
EPS (TTM) (€) | -0.863 | ||
Beta | 2.84 | ||
Volatility % | 204.68 | ||
14-Day RSI | 39.67 | ||
14-Day ATR (€) | 0.256038 | ||
20-Day SMA (€) | 4.663 | ||
12-1 Month Momentum % | 306.44 | ||
52-Week Range (€) | 0.867 - 5.59 | ||
Shares Outstanding (Mil) | 44.68 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cardiff Oncology Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cardiff Oncology Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cardiff Oncology Inc Frequently Asked Questions
What is Cardiff Oncology Inc(FRA:XE7C)'s stock price today?
When is next earnings date of Cardiff Oncology Inc(FRA:XE7C)?
Does Cardiff Oncology Inc(FRA:XE7C) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |